Last reviewed · How we verify
Nicorette Inhaler
Nicorette Inhaler delivers nicotine through inhalation to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.
Nicorette Inhaler delivers nicotine through inhalation to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid in nicotine-dependent patients.
At a glance
| Generic name | Nicorette Inhaler |
|---|---|
| Also known as | Nicorette Inahler, NPN: #02241742 |
| Sponsor | Ottawa Heart Institute Research Corporation |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
The inhaler provides a rapid, localized delivery of nicotine to the respiratory tract and systemic circulation. Nicotine acts as an agonist at nicotinic acetylcholine receptors, particularly in the central nervous system, mimicking the effects of smoking and thereby alleviating withdrawal symptoms and reducing the urge to smoke. This allows smokers to gradually reduce their dependence on cigarettes.
Approved indications
- Smoking cessation aid
Common side effects
- Throat irritation
- Cough
- Mouth irritation
- Hiccups
- Nausea
- Headache
Key clinical trials
- Cytisine vs Nicotine Replacement Therapy (NA)
- Pharmacist Intervention to Improve Smoking Cessation (NA)
- Lemongrass (Cymbopogon Citratus) on Nicotine Dependence, Cotinine Levels, and Related Biomarkers in Adult Smokers (NA)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial (PHASE4)
- Evaluation of Cessation Preferences of Menthol Smoker (NA)
- A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product (NA)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicorette Inhaler CI brief — competitive landscape report
- Nicorette Inhaler updates RSS · CI watch RSS
- Ottawa Heart Institute Research Corporation portfolio CI